Salt Lake City, Utah – USANA Health Sciences, Inc. (NYSE: USNA) announced preliminary fiscal year 2025 net sales and initial net sales guidance for fiscal year 2026 ahead of its presentation at the 28th Annual ICR Conference. At the conference, Doug Hekking, CFO, and Walter Noot, COO, will discuss USANA’s strategy, including the Company’s initial fiscal year 2026 sales outlook.
Preliminary Fiscal Year 2025 Net Sales Results
The Company currently anticipates fiscal year 2025 consolidated net sales of approximately $925 million, ahead of its most recently issued guidance of approximately $920 million.
Initial Fiscal Year 2026 Net Sales Outlook
The Company is issuing its initial net sales outlook for fiscal year 2026 in the range of $925 million to $1.0 billion.
The Company’s initial fiscal 2026 net sales outlook reflects:
Net sales from USANA, our core nutritional business, of $720 to $765 million (compared to preliminary net sales for fiscal 2025 of approximately $777 million);
Net sales from Hiya of $140 to $155 million (compared to preliminary net sales for fiscal 2025 of approximately $132 million);
Net sales from Rise Wellness of $65 to $80 million (compared to preliminary net sales for fiscal 2025 of approximately $16 million); and
Fiscal 2026 is a 52-week year, one week less of net